Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

A new campaign from Opella, Sanofi’s consumer health unit, is a royal flush. | A new campaign from Opella, Sanofi’s consumer ...

The survey suggests ads can improve health management. Almost half of patients said ads help them make informed decisions ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...

Thermo Fisher Scientific is responsible for helping to produce some of the hottest drugs on the market, including Novo ...

AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion.

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

Through allocations, Baxter is limiting how much customers can order based on their past purchases, medical necessity and ...

With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...